当前位置: X-MOL 学术J. Control. Release › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The role of liposomes in clinical nanomedicine development. What now? Now what?
Journal of Controlled Release ( IF 10.5 ) Pub Date : 2019-12-14 , DOI: 10.1016/j.jconrel.2019.12.023
Daan J A Crommelin 1 , Peter van Hoogevest 2 , Gert Storm 1
Affiliation  

The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: 'where to go with nanomedicines'? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved and marketed liposome-drug combinations provides these insights.

中文翻译:

脂质体在临床纳米医学发展中的作用。现在怎么办?怎么办?

在过去的20年中,学术界对“纳米医学”的兴趣迅速增长,并且成功的主张引发了反思的呼吁。本评论的正文主要是回答以下问题:“纳米药物在哪里”?未来的研究重点将根据迄今为止在纳米医学广泛领域中最成功的纳米药物家族的经验来概述:脂质体。对当前临床测试,批准和销售的脂质体-药物组合的分析提供了这些见解。
更新日期:2019-12-17
down
wechat
bug